LAUSR

reduces the need for additional uterotonics compared to oxytocin, but does not reduce PPH. Method: We performed a prospective cohort study of 2499 patients in Lyell McEwin Hospital, South Australia. Between 1st January 200831st March 2009 all women undergoing caesarean section received prophylactic oxytocin (Syntocinon) 10-unit bolus at time of delivery. Between 1st April 2009 – 31st December 2010 patients received 100 μg Carbetocin (Duratocin Ferring). Primary outcomes were PPH (blood loss > 1000 mL) and the requirement for secondary uterotonics. Results: We studied 1467 patients who received carbetocin and 1020 who received Syntocinon. The incidence of PPH was 6.7% versus 7.4% for carbetocin and syntocinon respectively (OR 0.84, 95% CI 0.621.16). Lower rates of moderate blood loss (500-999 mL) were observed for carbetocin; 11.0% versus 16.2% (OR 0.63, 95% CI 0.50-0.80). Secondary uterotonic treatment of PPH was required 20.1% less for carbetocin group (27.6% versus 47.7%) (OR 0.42, 95% CI 0.35-0.50). Conclusions: In this large cohort study, carbetocin reduced the occurrence of moderate blood loss and requirement for additional uterotonics, but not severe haemorrhage.